ArticlePLoS neglected tropical diseases2025
Decentralization of snakebite antivenom treatment to indigenous community health centers in the Brazilian Amazon: From demand to the first treatment (the SAVING Program).
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Strengthening public health programmes and the antivenom ecosystem: strategic policy priorities to combat envenomation by animal bites and stings in Latin America and the Caribbean.Journal of global health · 2026Article
- Effectiveness, safety, and implementation outcomes of a decentralization program to deliver antivenoms in the Western Brazilian Amazonia: The SAVING program.PLoS neglected tropical diseases · 2026Article
- Ethical considerations in decentralizing antivenom treatment in indigenous territories of the Brazilian Amazonia.PLoS neglected tropical diseases · 2026Article
- Snakes and snakebites in the munduruku cosmology and medicine, central Brazilian Amazonia.PLoS neglected tropical diseases · 2026Article
- Snakebite Envenomations In The Brazilian Amazon: A Little Less Neglected.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Brazilian antivenoms have excellent efficacy in recovering venom-induced coagulopathy, in addition to having a good safety profile with only 10% of patients experiencing a mild reaction such as urticaria or pruritus. More than 3.5 hundred thousand snakebite antivenom vials are produced per year, and all the batches are acquired by the Ministry of Health and distributed free of charge to 2,200 hospitals across the national territory. However, these health facilities are unevenly distributed across the territory, so that the distance a patient needs to travel to receive care is much greater in the Amazon region in comparison to the extra-Amazonia region, leading to a huge access barrier in this region. The lack of access to healthcare facilities for snakebite patients may be greater than 30% in some regions of the Amazonia. The decentralization of SBE treatment with antivenoms to the scope of indigenous community health centers requires the discussion of proper organizational designs and arrangements of practices based on the user needs, singularities of the territory, and the clinical reality of the indigenous populations. In this report, we describe a successful experience of decentralization of antivenom treatment for an indigenous health unit in the Brazilian Amazon, which provides a platform to improve the lives of SBE patients at risk of this life-threatening condition. In this work, we report the experience in the development and implementation of a program to decentralize antivenom treatment for indigenous communities, which represents a significant change in the national policy for snakebite control, with a potential impact on reducing morbidity and mortality from this health problem. In the next steps, SAVING Program will be evaluated through mixed-method studies in regards team and community's experience within the program, aiming to identify barriers, perceptions about the implementation process, and facilitators for the maintenance/sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.